Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis, Inc. (EXEL) is an oncology-focused biopharmaceutical company whose news flow centers on cancer therapeutics, clinical trial milestones and financial performance. The company’s updates frequently highlight the commercial progress of its cabozantinib franchise, marketed in the U.S. as CABOMETYX and COMETRIQ, as well as pivotal data and regulatory steps for its investigational kinase inhibitor zanzalintinib.
Investors following EXEL news can expect regular announcements on quarterly and annual financial results, including net product revenues for the cabozantinib franchise, research and development spending and stock repurchase authorizations. Exelixis also issues news releases around guidance for upcoming fiscal years and commentary from management on commercial and pipeline priorities.
A significant portion of Exelixis’ news coverage focuses on clinical and regulatory developments. Recent communications describe detailed results from the STELLAR-303 phase 3 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer, the planned and ongoing STELLAR-304 and STELLAR-311 pivotal trials in renal cell carcinoma and neuroendocrine tumors, and collaborations such as STELLAR-316 with Natera’s Signatera assay for molecular residual disease–guided therapy. Additional news addresses subgroup analyses from the CABINET trial of CABOMETYX in advanced neuroendocrine tumors and regulatory approvals for cabozantinib-based therapies in various indications.
Corporate and investor-relations events are another recurring theme in EXEL news. The company announces participation in major healthcare and investor conferences, R&D-focused webcasts and leadership changes disclosed via Form 8-K. For readers tracking oncology pipelines, solid tumor trial data and the commercial trajectory of CABOMETYX and zanzalintinib, the Exelixis news stream provides ongoing insight into the company’s scientific, clinical and financial developments.
Exelixis (NASDAQ: EXEL) has announced its participation in three upcoming investor conferences in May and June 2025. The company will participate in fireside chats at the TD Cowen 6th Annual Oncology Innovation Summit (May 27), the William Blair 45th Annual Growth Stock Conference (June 3), and the Jefferies Global Healthcare Conference 2025 (June 4).
All presentations will be accessible via webcast on www.exelixis.com under the Investors & News section's Event Calendar page. Replay recordings will remain available for at least 30 days after the events.
Exelixis (NASDAQ: EXEL) has initiated the dose-escalation stage of a Phase 1 clinical trial for XB628, a first-in-class bispecific antibody, in patients with recurrent advanced or metastatic solid tumors. The drug candidate was developed in collaboration with Invenra Inc., targeting NK group 2 member A (NKG2A) and programmed cell death-ligand 1 (PD-L1). XB628 functions as a natural killer (NK) cell engager, representing a novel approach in cancer immunotherapy.
Exelixis (NASDAQ: EXEL) has announced its participation in two major investor conferences in May 2025. The company will be featured in fireside chats at the BofA Securities 2025 Health Care Conference in Las Vegas on May 14 at 1:40 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference in New York City on May 20 at 10:30 a.m. ET.
Interested parties can access the webcasts through the Event Calendar page on www.exelixis.com under the Investors & News section. Replay recordings will remain available on the website for a minimum of 30 days after the events.
Exelixis (Nasdaq: EXEL) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 13, 2025, after market close. The company will hold a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update.
Interested participants can access the event through:
- Conference call: Registration required via provided link for dial-in number and unique PIN
- Live webcast: Available on www.exelixis.com under Investors & News section's Event Calendar page
- Replay: Will be archived on the company website for one year
Exelixis (NASDAQ: EXEL) has received FDA approval for CABOMETYX® (cabozantinib) to treat previously treated advanced neuroendocrine tumors (NET). The approval covers two specific indications: advanced pancreatic NET (pNET) and extra-pancreatic NET (epNET) in adults and pediatric patients 12 years and older.
The approval is based on the phase 3 CABINET trial results, which showed significant improvement in progression-free survival compared to placebo. CABOMETYX becomes the first and only FDA-approved systemic treatment for previously treated NET, regardless of primary tumor site, grade, somatostatin receptor expression, and functional status.
The National Comprehensive Cancer Network has updated its guidelines to include cabozantinib as a category 1 preferred regimen for well-differentiated advanced NET and category 2A for other forms. The safety profile was consistent with previous findings, though higher hypertension incidence was noted compared to other tumor types.
Exelixis (NASDAQ: EXEL) will present preclinical data for four pipeline molecules at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase both small molecule and biotherapeutic development candidates for advanced solid tumors.
The pipeline includes:
- XL495: A PKMYT1 inhibitor showing potential anti-tumor activity, currently in phase 1 clinical trials
- XB371: A tissue factor-targeting antibody-drug conjugate with planned FDA application in 2025
- XL309: A USP1 inhibitor active in BRCA 1/2 mutations, currently in phase 1 trials
- XB628: A first-in-class PD-L1 x NKG2A bispecific antibody with FDA-cleared IND application
Exelixis (Nasdaq: EXEL) has announced its participation in three major investor conferences this March. The company will engage in fireside chat presentations at:
- TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 9:50 a.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami on March 11 at 1:30 p.m. ET
- 2025 Leerink Partners Global Healthcare Conference in Miami on March 12 at 10:40 a.m. ET
All presentations will be accessible via webcast through the company's website at www.exelixis.com under the Investors & News section's Event Calendar page. Replay recordings will remain available for a minimum of 30 days after the events.
Exelixis (NASDAQ: EXEL) has announced a new $500 million stock repurchase program authorized by its Board of Directors, to be completed by December 31, 2025. The company plans to initiate this program after completing its current $500 million repurchase program, which is expected to conclude in Q2 2025.
This marks Exelixis' fourth stock repurchase program since March 2023, with the company having already returned over $1.2 billion to shareholders through these initiatives as of the end of fiscal year 2024. The repurchases may be executed through various methods, including open market purchases, block trades, and accelerated share repurchase transactions. The timing and volume of repurchases will be determined by factors including capital needs, alternative investments, stock price, and market conditions.
Exelixis (EXEL) announced final five-year follow-up results from the CheckMate -9ER trial evaluating CABOMETYX combined with Opdivo versus sunitinib in advanced kidney cancer patients. After 67.6 months median follow-up, the combination showed improved progression-free survival (PFS; HR: 0.58) and overall survival (OS; HR: 0.79) compared to sunitinib.
Key findings include median PFS of 16.4 vs 8.3 months and median OS of 46.5 vs 35.5 months for the combination vs sunitinib, respectively. The objective response rate was 55.7% for the combination versus 27.4% for sunitinib. The efficacy benefits were observed across different patient subgroups, including those with organ metastases and different risk classifications.
Safety profile remained manageable with no new safety signals reported, though Grade 3/4 adverse events were higher in the combination group (68%) versus sunitinib (55%).